880 SPLICE VARIANT VASCULAR ENDOTHELIAL GROWTH FACTOR-A LEVEL AS PROGNOSTIC INDICATOR OF PROGRESSION IN BLADDER CANCER

You have accessJournal of UrologyBladder Cancer: Basic Research1 Apr 2011880 SPLICE VARIANT VASCULAR ENDOTHELIAL GROWTH FACTOR-A LEVEL AS PROGNOSTIC INDICATOR OF PROGRESSION IN BLADDER CANCER Hugues Bittard, Isabelle Lascombe, Stéphane Bernardini, Eric Chabannes, and Sylvie Fauconnet Hugues BittardHugues Bittard Besancon, France More articles by this author , Isabelle LascombeIsabelle Lascombe Besancon, France More articles by this author , Stéphane BernardiniStéphane Bernardini Besancon, France More articles by this author , Eric ChabannesEric Chabannes Besancon, France More articles by this author , and Sylvie FauconnetSylvie Fauconnet Besancon, France More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.704AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES angiogenesis is required for growth as well as expansion of solid tumor and is mediated by soluble angiogenic factors such as vascular endothelial growth factor (VEGF). The present investigation was conducted to determine whether correlation exists between VEGF-A expression within the bladder tumor and clinicopathologic parameters and whether the tumor aggressiveness is depending on a specific VEGF-A isoform expression. METHODS total RNA was isolated from 37 specimens of bladder cancer and VEGF-A transcripts were detected by Northern-blotting analysis. Progression-free survival curve was plotted after mRNA quantification. VEGF-A splice variants were determined by southern-blotting and the expression intensity of each isoform was evaluated by quantitative real time RT-PCR in 20 new fresh frozen recent tumors. RESULTS northern-blotting analysis detected three VEGF-A transcripts of 5.2, 4.5 and 1.7 kb in length respectively. The VEGF-A transcripts levels were greater in cancer tissues than in normal urothelium, significantly higher in pT2-T4 than in pTa and pT1 urothelial tumors and thus, were correlated to the pathologic stage. Patients with higher VEGF-A mRNA levels had a significantly shorter survival without progression compared to those with lower levels. Three VEGF-A splice variants were detected namely, VEGF121, 165 and 189. VEGF121 and VEGF165 were expressed at the similar level. On the contrary, they were significantly more expressed than VEGF189 (p<0.05). The three isoforms were higher expressed in pT2 bladder cancers than in pTa tumors (p<0.05). There was only a significant correlation between the increased expression level of VEGF121 and 165 and the histological grade of the lesion (p<0.05). CONCLUSIONS VEGF-A mRNA level could serve as a prognostic indicator of progression in bladder cancer as well as the expression level of the different VEGF-A splice variants. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e352 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hugues Bittard Besancon, France More articles by this author Isabelle Lascombe Besancon, France More articles by this author Stéphane Bernardini Besancon, France More articles by this author Eric Chabannes Besancon, France More articles by this author Sylvie Fauconnet Besancon, France More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...